Fluvastatin sodium

Pricing Availability   Qty
Cat.No. 3309 - Fluvastatin sodium | C24H25FNNaO4 | CAS No. 93957-55-2
Description: Potent HMG-CoA reductase inhibitor
Chemical Name: (±)-(3R*,5S*,6E)-7-[3-(4-Fluorophenyl)-1-(1-methyethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid sodium salt
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews
Literature

Biological Activity

Orally active, potent and competitive HMG-CoA reductase inhibitor (IC50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo.

Compound Libraries

Fluvastatin sodium is also offered as part of the Tocriscreen Plus and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 433.45
Formula C24H25FNNaO4
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 93957-55-2
PubChem ID 76969265
InChI Key BNZHURJBOKXWJX-ZKBIPVLYSA-L
Smiles [Na+].[Na+].CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2.CC(C)N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 10.84 25
DMSO 43.34 100

Preparing Stock Solutions

The following data is based on the product molecular weight 433.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.31 mL 11.54 mL 23.07 mL
5 mM 0.46 mL 2.31 mL 4.61 mL
10 mM 0.23 mL 1.15 mL 2.31 mL
50 mM 0.05 mL 0.23 mL 0.46 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Dansette et al (2000) HMG-CoA reductase activity in human liver microsomes: comparative inhibition by STAT. Exp.Toxicol.Pathol. 52 145 PMID: 10965989

Yamamoto et al (2001) Antioxidative effects of fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on peroxidation of phospholipid liposomes. J.Pharm.Pharmacol. 53 227 PMID: 11273020

Turner et al (2007) Comparison of the efficacies of five different STAT on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J.Cardiovasc.Pharmacol. 50 458 PMID: 18049315


If you know of a relevant reference for Fluvastatin sodium, please let us know.

View Related Products by Target

View Related Products by Product Action

View all HMG-CoA Reductase Inhibitors

Keywords: Fluvastatin sodium, Fluvastatin sodium supplier, HMG-CoA, reductases, inhibitors, inhibits, statins, Reductase, 3309, Tocris Bioscience

5 Citations for Fluvastatin sodium

Citations are publications that use Tocris products. Selected citations for Fluvastatin sodium include:

Vainio et al (2011) Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by STAT. Am J Physiol Renal Physiol 2 1176 PMID: 22202492

Rojo-Arreola et al (2014) Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS One 9 e87594 PMID: 24489942

Park et al (2016) Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 17 914 PMID: 27270401

Li and Fountain (2012) Fluvastatin suppresses native and recombinant human P2X4 receptor function. Purinergic Signal 8 311 PMID: 22222818

Bergman et al (2011) Studies on the antibacterial effects of STAT--in vitro and in vivo. PLoS One 6 e24394 PMID: 21912631


Do you know of a great paper that uses Fluvastatin sodium from Tocris? Please let us know.

Reviews for Fluvastatin sodium

There are currently no reviews for this product. Be the first to review Fluvastatin sodium and earn rewards!

Have you used Fluvastatin sodium?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Epilepsy

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.